España
India
Italia
대한민êµ
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Genmab
GNMSF
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$197.87
2.23
1.14%
At close: -
$282.50
84.63
42.77%
After Hours: Feb 28, 9:28 AM EDT
Get Report
Comment
Genmab (GNMSF) Forecast
News
Earnings
Genmab (GNMSF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Genmab (OTC:GNMSF) Stock
Genmab Stock (OTC: GNMSF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, August 06, 2020
GlaxoSmithKline Gets FDA Approval For Blood Cancer Drug
Shivdeep Dhaliwal
Tuesday, March 24, 2020
Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights
Tuesday, August 13, 2019
Stocks That Hit 52-Week Highs Of Tuesday
Lisa Levin
Monday, August 12, 2019
Stocks That Hit 52-Week Highs Of Monday
Lisa Levin
Sunday, October 25, 2015
Genmab Announces $3M Milestone Payment in DuoBody Platform Collaboration with Janssen
Benzinga
Monday, October 05, 2015
Genmab Reaches $3M Milestone Payment in DuoBody Platform Collaboration with Janssen
Benzinga
Friday, September 25, 2015
US Stock Futures Jump Ahead Of GDP Report
Benzinga
Genmab Announces CHMP Grants Accelerated Assessment for Daratumumab for Double Refractory Multiple Myeloma
Benzinga
Saturday, September 19, 2015
Genmab Announces FDA Grants Priority Review for Ofatumumab as Maintenance Therapy for Relapsed CLL
Benzinga
Friday, September 04, 2015
Genmab Announces FDA Grants Priority Review for Daratumumab for Double Refractory Multiple Myeloma
Benzinga
Friday, August 14, 2015
US Stock Futures Slip Ahead Of Economic Data
Benzinga
Genmab Enters Commercial License Agreement with Novo Nordisk for DuoBody Technology
Benzinga
Monday, April 27, 2015
Genmab Announces Phase III Study of Arzerra Met Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed CLL
Benzinga
Monday, March 16, 2015
Genmab Retains Partial Rights for HuMax-TAC-ADC; Won't Exercise Co-development Right
Benzinga
Monday, August 11, 2014
Genmab Announces Jannsen to Start New Phase III Study of Daratumumab in Front Line Multiple Myeloma
Benzinga
